AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28109962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate
Number of subjects: 1341
Study 28109962 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Organ Failure Assessment score
Number of subjects: 1341
Study 28109962 — intervention group
Group type: EXPERIMENTAL
Intervention: sFLT-1 (adjusted for age, presence of cancer, and Charlson comorbidity score)
Number of subjects: 1341
Study 25412300 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (EX), combining continuous steady-state and interval cycling at various intensities, in combination with unsupervised moderate intensity aerobic activity and conventional diabetic management
Number of subjects: 40
Study 25412300 — intervention group
Group type: COMPARATOR
Intervention: Conventional management alone (CON)
Number of subjects: 40
Study 23470235 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream applied twice daily for 1 month
Number of subjects: 45
Study 23470235 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 1% ointment applied twice daily for 1 month
Number of subjects: 45
Study 21528627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity vibration (LIV) at 0.27 +/- 0.11 g; 34 Hz
Number of subjects: 17
Study 21528627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity vibration (LIV) at 0.44 +/- 0.18 g; 34 Hz
Number of subjects: 17
Study 21528627 — intervention group
Group type: COMPARATOR
Intervention: Control group (able-bodied)
Number of subjects: 17
Study 18609024 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group exercises based on a personal construct approach
Number of subjects: 32
Study 16062032 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study 11887543 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (group 1)
Number of subjects: 111
Study 11887543 — intervention group
Group type: COMPARATOR
Intervention: Compressed air (group 2)
Number of subjects: 111
Study 11783255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sini Decoction (SND), 25 ml daily from 3 days before operation to the third day after operation.
Number of subjects: 40
Study 11783255 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 40
Study 8721897 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) + Lentinan
Number of subjects: 107
Study 8721897 — intervention group
Group type: COMPARATOR
Intervention: Didanosine (ddI)
Number of subjects: 107
Study 2551560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (25, 50, and 50 mg bolus injections at 15-minute intervals)
Number of subjects: 16
Study 2551560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2551560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 16
Study 391093 — intervention group
Group type: EXPERIMENTAL
Intervention: New lancet with a point length of 1.0 mm
Number of subjects: 0
Study 391093 — intervention group
Group type: COMPARATOR
Intervention: Conventional prick test method
Number of subjects: 0
Study 31693083 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block (SGB) treatment
Number of subjects: 113
Study 31693083 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 113
Study 30817018 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 131
Study 30817018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 28379017 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 50
Study 28379017 — intervention group
Group type: COMPARATOR
Intervention: Analgosedation (AS)
Number of subjects: 50
Study 26887208 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion applied to Guanyuan (GV 4) for 40 min, once daily for (7 +/- 2) days in one menstrual cycle, for 3 menstrual cycles.
Number of subjects: 189
Study 26887208 — intervention group
Group type: COMPARATOR
Intervention: Conventional warm sensation moxibustion.
Number of subjects: 189
Study 22805254 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure plus routine care
Number of subjects: 78
Study 22805254 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 78
Study 22453108 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart-alert sticker ('Do you leak urine?')
Number of subjects: 190
Study 22453108 — intervention group
Group type: COMPARATOR
Intervention: No sticker (control group)
Number of subjects: 190
Study 22453108 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart-alert sticker
Number of subjects: 190
Study 19968383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 113
Study 19968383 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 113
Study 19968383 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (ADM)
Number of subjects: 113
Study 19968383 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-criticism
Number of subjects: 113
Study 16289676 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-adhesive 0.2% chlorhexidine gel applied once during surgery
Number of subjects: 103
Study 16289676 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel applied once during surgery
Number of subjects: 103
Study 15250781 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-ordered serial comparison or verification procedure
Number of subjects: 0
Study 15250781 — intervention group
Group type: EXPERIMENTAL
Intervention: Search model extensions
Number of subjects: 0
Study 12478901 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11 (50 micrograms/kg/d) administered subcutaneously for 14 consecutive days after chemotherapy
Number of subjects: 109
Study 12478901 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11 during cycle A
Number of subjects: 109
Study 12478901 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IL-11 during cycle B)
Number of subjects: 109
Study 9468251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 292
Study 9468251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 292
Study 9468251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg
Number of subjects: 292
Study 9468251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 9468251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (all doses)
Number of subjects: 292
Study 7621277 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU of alpha-2b IFN three times per week for 12 months
Number of subjects: 48
Study 7621277 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 MU of alpha-2a IFN three times per week for one year
Number of subjects: 48
Study 7621277 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 48
Study 2122719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactase-containing tablets
Number of subjects: 18
Study 2122719 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 18
Study 350398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ftorafur with mitomycin C
Number of subjects: 52
Study 350398 — intervention group
Group type: COMPARATOR
Intervention: Ftorafur with methyl-CCNU
Number of subjects: 52
Study 30377198 — intervention group
Group type: EXPERIMENTAL
Intervention: Epacadostat (IDO1-selective inhibitor) in combination with pembrolizumab
Number of subjects: 0
Study 30377198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28010051 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0
Study 28010051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25576753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified infliximab regimen (5mg/kg every 4 weeks for 12 weeks)
Number of subjects: 42
Study 23242365 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 21276122 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of lycopene for 12 weeks
Number of subjects: 28
Study 21276122 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 28
Study 19738090 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) algorithm for antibiotic administration
Number of subjects: 1359
Study 17375876 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 120
Study 17375876 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 120
Study 17375876 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120
Study 15499533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) at 6.4 mg/kg DHA
Number of subjects: 731
Study 15499533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine plus additional artemisinin derivative (DP+) at 12 mg/kg
Number of subjects: 731
Study 15499533 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine plus artesunate (MAS3)
Number of subjects: 731
Study 15499533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 731
Study 15499533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine plus additional artemisinin derivative (DP+)
Number of subjects: 731
Study 11552664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine treatment
Number of subjects: 0
Study 11552664 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9591811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath-PUVA-311 nm
Number of subjects: 12
Study 9591811 — intervention group
Group type: COMPARATOR
Intervention: Bath-PUVA
Number of subjects: 12
Study 8148194 — intervention group
Group type: EXPERIMENTAL
Intervention: Acorn nebulizer attached to the Mizer Aerosol Conservation Device (MACD)
Number of subjects: 12
Study 8148194 — intervention group
Group type: COMPARATOR
Intervention: Acorn nebulizer and mouthpiece alone
Number of subjects: 12
Study 2971549 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (mean final daily dose: 13.1 mg)
Number of subjects: 40
Study 2971549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31529462 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 885
Study 31529462 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI)
Number of subjects: 885
Study 31529462 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA score
Number of subjects: 885
Study 29519716 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-month regimen of moxifloxacin, pasiniazid, rifabutin, ethambutol, and pyrazinamide (n = 626)
Number of subjects: 917
Study 29519716 — intervention group
Group type: COMPARATOR
Intervention: 8-month regimen of isoniazid, rifampicin, and streptomycin (n = 291)
Number of subjects: 917
Study 29519716 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-month regimen for patients with multidrug-resistant TB (MDR-TB)
Number of subjects: 917
Study 29519716 — intervention group
Group type: COMPARATOR
Intervention: 8-month regimen for patients with multidrug-resistant TB (MDR-TB)
Number of subjects: 917
Study 26179561 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (P)
Number of subjects: 48
Study 26179561 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/Remifentanil (PR)
Number of subjects: 48
Study 26179561 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/Remifentanil/S-Ketamine (PRK)
Number of subjects: 48
Study 26179561 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anesthesia)
Number of subjects: 48
Study 26179561 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 48
Study 26179561 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia (general)
Number of subjects: 48
Study 24929949 — intervention group
Group type: EXPERIMENTAL
Intervention: fosamprenavir/ritonavir 700/100 mg b.i.d. for 16 days with a single dose of olanzapine 15 mg on Day 13
Number of subjects: 24
Study 24929949 — intervention group
Group type: COMPARATOR
Intervention: olanzapine 10 mg alone
Number of subjects: 24
Study 22292421 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural neurocardiac training (with heart rate variability biofeedback)
Number of subjects: 45
Study 22292421 — intervention group
Group type: COMPARATOR
Intervention: Autogenic relaxation
Number of subjects: 45
Study 20827655 — intervention group
Group type: EXPERIMENTAL
Intervention: Slide ergometer
Number of subjects: 7
Study 20827655 — intervention group
Group type: COMPARATOR
Intervention: Stationary ergometer
Number of subjects: 7
Study 17562278 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I radioactive seed implantation
Number of subjects: 20
Study 15718269 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 10
Study 15718269 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 10
Study 15718269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12442349 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg via 15 min infusion every 3-4 weeks)
Number of subjects: 1189
Study 12442349 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (90 mg via 2 hr infusion)
Number of subjects: 1189
Study 12442349 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg)
Number of subjects: 1189
Study 12442349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1189
Study 10456490 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-strength grapefruit juice
Number of subjects: 10
Study 10456490 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-strength grapefruit juice
Number of subjects: 10
Study 10456490 — intervention group
Group type: COMPARATOR
Intervention: Control (200 ml orange juice)
Number of subjects: 10
Study 8553212 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic assisted colectomy (LAC)
Number of subjects: 0
Study 8553212 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy (OC)
Number of subjects: 0
Study 1695310 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 16
Study 1695310 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 16
Study 445503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide alone (1 g/m2)
Number of subjects: 0
Study 445503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (500 mg/m2) plus Adriamycin (40 mg/m2)
Number of subjects: 0
Study 445503 — intervention group
Group type: COMPARATOR
Intervention: Combination regimen (Cyclophosphamide plus Adriamycin)
Number of subjects: 0
Study 445503 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30202898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Monte Carlo adaptation for updating posterior distribution
Number of subjects: 0
Study 30202898 — intervention group
Group type: EXPERIMENTAL
Intervention: More complex statistical models
Number of subjects: 0
Study 31109746 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mm hard acrylic, maxillary stabilization-type splint for 3 months
Number of subjects: 24
Study 31109746 — intervention group
Group type: COMPARATOR
Intervention: No treatment after SF aspiration
Number of subjects: 24
Study 29878718 — intervention group
Group type: EXPERIMENTAL
Intervention: Double diluted abobotulinum toxin type A (Dysport) (dilution of 15 mL to give 3.33 units per 0.1 mL)
Number of subjects: 10
Study 29878718 — intervention group
Group type: EXPERIMENTAL
Intervention: Common concentration of abobotulinum toxin type A (Dysport) (dilution of 7.5 mL to give 6.67 units per 0.1 mL)
Number of subjects: 10
Study 27251910 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care with input from a homeless care team
Number of subjects: 410
Study 27251910 — intervention group
Group type: COMPARATOR
Intervention: Standard care (all management by the hospital‐based clinical team)
Number of subjects: 410
Study 25260191 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized parent education intervention (12 sessions)
Number of subjects: 66
Study 25260191 — intervention group
Group type: COMPARATOR
Intervention: Monitoring control group (4 sessions of behavioral support)
Number of subjects: 66
Study 25260191 — intervention group
Group type: COMPARATOR
Intervention: Both groups (treatment and control)
Number of subjects: 66
Study 22418908 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg once daily
Number of subjects: 4020
Study 22418908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4020
Study 20923006 — intervention group
Group type: EXPERIMENTAL
Intervention: Static headspace (s‐HS) at 40 degrees C
Number of subjects: 0
Study 20923006 — intervention group
Group type: EXPERIMENTAL
Intervention: Static headspace (s‐HS) at 60 degrees C
Number of subjects: 0
Study 20923006 — intervention group
Group type: EXPERIMENTAL
Intervention: Headspace solid phase micro extraction (HS‐SPME)
Number of subjects: 0
Study 20923006 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid‐liquid partition
Number of subjects: 0
Study 17532102 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee replacement (TKR)
Number of subjects: 42
Study 17532102 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 16314629 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy
Number of subjects: 1147
Study 16314629 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1147
Study 17083180 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment (8 modes)
Number of subjects: 336
Study 10634832 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Triggered Ventilation (PTV)
Number of subjects: 924
Study 10634832 — intervention group
Group type: COMPARATOR
Intervention: Conventional Ventilation (IMV)
Number of subjects: 924
Study 8796182 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose FSH (150 IU)
Number of subjects: 0
Study 8796182 — intervention group
Group type: COMPARATOR
Intervention: Low-dose FSH
Number of subjects: 0
Study 1643014 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose cytarabine (200 mg/m2/d by continuous infusion)
Number of subjects: 101
Study 1643014 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine (500 mg/m2 every 12 h)
Number of subjects: 101
Study 6380981 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual anastomosis
Number of subjects: 0
Study 6380981 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapler anastomosis
Number of subjects: 0
Study 6380981 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastomosis at 6 cm from anocutaneous line
Number of subjects: 0
Study 6380981 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastomosis above 6 cm from anocutaneous line
Number of subjects: 0
Study 6380981 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastomosis below 6 cm from anocutaneous line
Number of subjects: 0
Study 31470796 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐Y™ jelly lubrication
Number of subjects: 0
Study 29326183 — intervention group
Group type: EXPERIMENTAL
Intervention: vNOTES (transvaginal natural orifice transluminal endoscopic surgery)
Number of subjects: 0
Study 29326183 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic treatment (control)
Number of subjects: 0
Study 29326183 — intervention group
Group type: EXPERIMENTAL
Intervention: vNOTES
Number of subjects: 0
Study 26858219 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Interlaminar (MIL) approach
Number of subjects: 84
Study 26858219 — intervention group
Group type: COMPARATOR
Intervention: Transforaminal (TF) approach
Number of subjects: 84
Study 25726658 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Xuefuzhuyutang
Number of subjects: 137
Study 25726658 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 137
Study 22729800 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive sensory feedback system using air-mediated pressure from silicone pads on the prosthetic hand to the amputation stump.
Number of subjects: 32
Study 22729800 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-amputees
Number of subjects: 32
Study 22729800 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans‐radial amputees
Number of subjects: 32
Study 20018567 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 0
Study 20018567 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 18351298 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education (fact sheet explaining importance of reducing IOP and efficacy of bimatoprost)
Number of subjects: 106
Study 18351298 — intervention group
Group type: COMPARATOR
Intervention: No intervention (only instructed to instil bimatoprost daily)
Number of subjects: 106
Study 18351298 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education (fact sheet)
Number of subjects: 106
Study 18351298 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 106
Study 18351298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost therapy
Number of subjects: 106
Study 15903375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cs-Rr (Cordyceps sinensis and Rhodiola rosea)
Number of subjects: 8
Study 15903375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12771264 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone
Number of subjects: 29
Study 12771264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 10384851 — intervention group
Group type: EXPERIMENTAL
Intervention: Naseptin antiseptic nasal carrier cream alone (Group A)
Number of subjects: 64
Study 10384851 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Naseptin cream and silver nitrate cautery (Group B)
Number of subjects: 64
Study 10384851 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 64
Study 10384851 — intervention group
Group type: COMPARATOR
Intervention: Comparison of age groups in both treatment arms
Number of subjects: 64